Introduction: Continuous glucose monitoring (CGM) is increasingly being used in the management of diabetes. Racial disparities in use of CGM may contribute to disparities in health outcomes. Studies have shown disparities in use of CGM among different races. However, most of these studies were done in the pediatric population.
Objectives: To determine whether there are racial differences in the use of CGM in adults with type 1 or type 2 diabetes.
Methodology: In this cross-sectional study, the TriNetX query tool was used to search electronic medical records of patients seen at Penn State Health Hershey Medical Center. Inclusion Criteria were age 18 to 80 years old, and type 1 or type 2 diabetes. Patient measures collected include age, gender, race, ethnicity, using CGM or not, using insulin or not, and A1c.
Results: The total number of patients with type 1 or type 2 diabetes was 73,210. Among those, 1,330 patients were using CGM, including 1,090 White patients (1.88% of Whites with type 1 or type 2 diabetes) , 80 Black patients (1.39% of diabetic Blacks) , 79 Hispanic patients (1.82 % of diabetic Hispanics) , and 26 Asian patients (1.77% of diabetic Asians) . In patients with type 2 diabetes who are on insulin, CGM use was as the following: 2.03% of White patients, 1.% of Black patients, 1.09% of Hispanic patients, and 1.89% of Asian patients. Among insulin-treated patients with type 2 diabetes, mean A1c was 7.76% in those using CGM, compared to 7.89% in those not using CGM. Among patients with type 1 diabetes, 9.13% of White patients, 6.84% of Black patients, 7.57% of Hispanic patients and 8.82% of Asian patients were using CGM. In patients with type 1 diabetes, mean A1C was 8.43% in those using CGM and 8.36% in those not using CGM.
Discussion: Only patients who were billed for CGM during visits were included as CGM users in the study, which could result in fewer patients identified as CGM users. Rates of CGM use were lowest in Black and Hispanic adults indicating that racial and ethnic disparities exist in the use of CGM among adults with diabetes.
S.M.Aljedaani: None. A.S.Siddiqui: Advisory Panel; Alexion Pharmaceuticals, Inc. N.Raja-khan: None.